Alpha 2.0
Login Register
» Authors » G van Tienhoven

G van Tienhoven

Explore the profile of G van Tienhoven including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 63
Citations 1320
Followers 0
Related Specialties
Oncology
Radiology
General Medicine
Top 10 Co-Authors
M G Besselink
J W Wilmink
I Q Molenaar
H C van Santvoort
H W M van Laarhoven
B Groot Koerkamp
H Bartelink
H M Verkooijen
C H J van Eijck
O R Busch
Published In
Radiother Oncol
Ned Tijdschr Geneeskd
Eur J Cancer
Ann Oncol
BMC Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol
Stoop T, Seelen L, van t Land F, van der Hout A, Scheepens J, Ali M, et al.
BMC Cancer . 2025 Feb; 25(1):299. PMID: 39972248
Background: The introduction of (m)FOLFIRINOX and gemcitabine-nab-paclitaxel has changed the perspective for patients with locally advanced pancreatic cancer (LAPC). Consequently, in experienced centres 23% of patients with LAPC undergo a...
2.
Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within...
Daamen L, van Goor I, Groot V, Andel P, Brosens L, Busch O, et al.
Trials . 2024 Jul; 25(1):456. PMID: 38970096
No abstract available.
3.
Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design
Daamen L, van Goor I, Groot V, Andel P, Brosens L, Busch O, et al.
Trials . 2024 Jun; 25(1):401. PMID: 38902836
Background: Disease recurrence remains one of the biggest concerns in patients after resection of pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most patients experience local and/or distant PDAC recurrence...
4.
Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
van Dam J, Verkolf E, Dekker E, Bonsing B, Bratlie S, Brosens L, et al.
BMC Cancer . 2023 Aug; 23(1):728. PMID: 37550634
Background: Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvant...
5.
Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single center prospective cohort
Doppenberg D, Lagerwaard F, van Dieren S, Meijerink M, van der Vliet J, Besselink M, et al.
Front Oncol . 2023 Jun; 13:1149961. PMID: 37324027
Background: The role of stereotactic ablative radiation therapy (SABR) as local treatment option after chemotherapy for locally advanced pancreatic cancer (LAPC) is evolving. However adequate patient selection criteria for SABR...
6.
Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE)
van Goor I, Daamen L, Besselink M, Bruynzeel A, Busch O, Cirkel G, et al.
Trials . 2023 Jan; 24(1):55. PMID: 36694252
No abstract available.
7.
Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design
Doppenberg D, Besselink M, van Eijck C, Intven M, Koerkamp B, Kazemier G, et al.
BMC Cancer . 2023 Jan; 23(1):70. PMID: 36670370
No abstract available.
8.
Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design
Doppenberg D, Besselink M, van Eijck C, Intven M, Koerkamp B, Kazemier G, et al.
BMC Cancer . 2022 Dec; 22(1):1363. PMID: 36581914
Background: Significant comorbidities, advanced age, and a poor performance status prevent surgery and systemic treatment for many patients with localized (non-metastatic) pancreatic ductal adenocarcinoma (PDAC). These patients are currently treated...
9.
A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE)
van Goor I, Daamen L, Besselink M, Bruynzeel A, Busch O, Cirkel G, et al.
Trials . 2022 Oct; 23(1):913. PMID: 36307892
Background: Disease recurrence is the main cause of mortality after resection of pancreatic ductal adenocarcinoma (PDAC). In 20-30% of resected patients, isolated local PDAC recurrence occurs. Retrospective studies have suggested...
10.
Correction: Quantifying the reduction of respiratory motion by mechanical ventilation with MRI for radiotherapy
van Kesteren Z, Veldman J, Parkes M, Stevens M, Balasupramaniam P, van den Aardweg J, et al.
Radiat Oncol . 2022 Jun; 17(1):113. PMID: 35765010
No abstract available.